You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CAR-NK

Showing 1 - 25 of 1,933
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Multiple Myeloma, Plasma Cell Leukemia Trial in Shanghai (Human BCMA targeted CAR-NK cells injection)

Recruiting
  • Multiple Myeloma
  • Plasma Cell Leukemia
  • Human BCMA targeted CAR-NK cells injection
  • Shanghai, Shanghai, China
    Shanghai Changzheng Hospital
Sep 13, 2023

Ovarian Cancer Trial in Hangzhou (NKG2D CAR-NK)

Recruiting
  • Ovarian Cancer
  • NKG2D CAR-NK
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
Mar 26, 2023

Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Tumor (BPDCN), Relapse Leukemia Trial in Taiyuan (CD123 targeted

Recruiting
  • Acute Myeloid Leukemia
  • +3 more
  • CD123 targeted CAR-NK cells
  • Taiyuan, Shanxi, China
    Shanxi Bethune Hospital
Aug 28, 2023

Immunotherapy, Multiple Myeloma Trial in Zhengzhou (Chimeric Antigen Receptor NK Cell Injection Targeting BCMA (BCMA CAR-NK))

Recruiting
  • Immunotherapy
  • Multiple Myeloma
  • Chimeric Antigen Receptor NK Cell Injection Targeting BCMA (BCMA CAR-NK)
  • Zhengzhou, Henan, China
    Henan Cancer Hospital
Dec 14, 2022

AML Trial in Hangzhou (NKG2D CAR-NK)

Recruiting
  • AML
  • NKG2D CAR-NK
  • Hangzhou, Zhejiang, China
  • +1 more
Feb 17, 2023

Refractory or Relapsed B-cell Non-Hodgkin Lymphoma Trial in Shanghai (dualCAR-NK19/70 cell)

Recruiting
  • Refractory or Relapsed B-cell Non-Hodgkin Lymphoma
  • dualCAR-NK19/70 cell
  • Shanghai, Shanghai, China
    Shanghai Tongji Hospital, Tongji University School of Medicine
Apr 24, 2023

Acute Lymphoblastic Leukemia, B-cell Lymphoma, Chronic Lymphocytic Leukemia Trial in Xuzhou (allogenic CD19-CAR-NK cells)

Recruiting
  • Acute Lymphoblastic Leukemia
  • +2 more
  • allogenic CD19-CAR-NK cells
  • Xuzhou, Jiangsu, China
    The Affiliated Hospital of Xuzhou Medical University
Feb 11, 2023

Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial in Hangzhou (BCMA CAR-NK, Cyclophosphamide, Fludarabine

Recruiting
  • Multiple Myeloma in Relapse
  • Multiple Myeloma, Refractory
  • BCMA CAR-NK
  • +2 more
  • Hangzhou, Zhejiang, China
  • +1 more
Feb 17, 2023

AML, Adult, Minimal Residual Disease Trial in Tianjin (CD33/CLL1 dual CAR-NK cell, Cyclophosphamid, Fludarabine)

Not yet recruiting
  • AML, Adult
  • Minimal Residual Disease
  • CD33/CLL1 dual CAR-NK cell
  • +5 more
  • Tianjin, China
    Institute of Hematology & Blood Diseases Hospital
Aug 4, 2023

Systemic Lupus Erythematosus (SLE) Trial in Shanghai (anti-CD19 CAR NK cells (KN5501))

Recruiting
  • Systemic Lupus Erythematosus (SLE)
  • anti-CD19 CAR NK cells (KN5501)
  • Shanghai, China
    Changhai Hospital
Aug 25, 2023

Diffuse Large B Cell Lymphoma Trial (anti-CD19 CAR NK cells)

Not yet recruiting
  • Diffuse Large B Cell Lymphoma
  • anti-CD19 CAR NK cells
  • (no location specified)
Dec 21, 2022

Adult Relapsed/Refractory B-cell Hematologic Malignancies Trial in Beijing (CD19-CAR-NK)

Recruiting
  • Adult Relapsed/Refractory B-cell Hematologic Malignancies
  • CD19-CAR-NK
  • Beijing, Beijing, China
    The Fifth Medical Center of Chinese People's Liberation Army (PL
Dec 1, 2022

B-cell Lymphoma, B-cell Leukemia Trial in Kunming (anti-CD19 UCAR-NK cells)

Withdrawn
  • B-cell Lymphoma
  • B-cell Leukemia
  • anti-CD19 UCAR-NK cells
  • Kunming, Yunnan, China
    Kunming Hope of Health Hospital
Nov 27, 2022

Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia Recurrent Trial in Beijing (CD123-CAR-NK cells)

Recruiting
  • Acute Myeloid Leukemia Refractory
  • Acute Myeloid Leukemia Recurrent
  • CD123-CAR-NK cells
  • Beijing, Beijing, China
    The Fifth Medical Center of Chinese People's Liberation Army (PL
Oct 24, 2022

B-cell Non Hodgkin Lymphoma Trial in Hanzhou (anti-CD19 CAR-NK)

Not yet recruiting
  • B-cell Non Hodgkin Lymphoma
  • anti-CD19 CAR-NK
  • Hanzhou, Zhejiang, China
    2nd Affiliated Hospital, School of Medicine, Zhejiang University
Jul 21, 2022

Solid Tumors Trial in Houston (Rimiducid, TROP2-CAR-NK Cells, Fludarabine phosphate)

Not yet recruiting
  • Solid Tumors
  • Houston, Texas
    M D Anderson Cancer Center
Sep 27, 2023

B-cell Non Hodgkin Lymphoma Trial in Hanzhou (CB dualCAR-NK19/70)

Not yet recruiting
  • B-cell Non Hodgkin Lymphoma
  • CB dualCAR-NK19/70
  • Hanzhou, Zhejiang, China
    2nd Affiliated Hospital, School of Medicine, Zhejiang University
Dec 25, 2022

Stage IV Ovarian Cancer, Testis Cancer, Refractory, Endometrial Cancer Recurrent Trial in Guangzhou (Claudin6 targeting CAR-NK

Recruiting
  • Stage IV Ovarian Cancer
  • +3 more
  • Claudin6 targeting CAR-NK cells
  • Guangzhou, Guangdong, China
    The Second Affiliated Hospital of Guangzhou Medical University
Jun 5, 2022

SCLC, Extensive Stage Trial in Tianjin (DLL3-CAR-NK cells)

Recruiting
  • SCLC, Extensive Stage
  • DLL3-CAR-NK cells
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Institute and Hospital
Aug 18, 2022

Pancreatic Cancer, Ovarian Cancer, Adenocarcinoma Trial in Houston (TROP2-CAR-NK, Cyclophosphamide, Fludarabine)

Not yet recruiting
  • Pancreatic Cancer
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Jun 27, 2023

AML, Adult Trial in Hangzhou (CLL1 CAR-NK cell injection)

Recruiting
  • AML, Adult
  • CLL1 CAR-NK cell injection
  • Hangzhou, Zhejiang, China
    Clinical research ethics committee of the first affiliated hospi
Aug 30, 2023

Safety and Efficacy Trial in Sanhe (CAR-NK cells)

Recruiting
  • Safety and Efficacy
  • CAR-NK cells
  • Sanhe, Hebei, China
    Hebei Yanda Lu Daopei Hospital
Feb 9, 2022

Gastroesophageal Junction (GEJ) Cancers, Advanced HNSCC Trial run by the NCI (N-803, Pembrolizumab, PD-L1 t-haNK)

Recruiting
  • Gastroesophageal Junction (GEJ) Cancers
  • Advanced HNSCC
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 26, 2023

Acute Lymphoblastic Leukemia Trial in Sanhe (CAR-NK-CD19 Cells)

Completed
  • Acute Lymphoblastic Leukemia
  • CAR-NK-CD19 Cells
  • Sanhe, Hebei, China
    Hebei Yanda Ludaopei Hospital
Nov 24, 2022

Refractory Metastatic Colorectal Cancer Trial in Hangzhou (NKG2D CAR-NK)

Recruiting
  • Refractory Metastatic Colorectal Cancer
  • NKG2D CAR-NK
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital, Zhejiang University
Jan 16, 2022